Contribution of rare variants in monogenic diabetes-genes to early-onset type 2 diabetes.


Journal

Diabetes & metabolism
ISSN: 1878-1780
Titre abrégé: Diabetes Metab
Pays: France
ID NLM: 9607599

Informations de publication

Date de publication:
09 2022
Historique:
received: 31 01 2022
revised: 14 04 2022
accepted: 22 04 2022
pubmed: 30 4 2022
medline: 21 9 2022
entrez: 29 4 2022
Statut: ppublish

Résumé

This study investigated whether rare, deleterious variants in monogenic diabetes-genes are associated with early-onset type 2 diabetes (T2D). A nested case-control study was designed from 9712 Italian patients with T2D. Individuals with age at diabetes onset ≤35 yrs (n = 300; cases) or ≥65 yrs (n = 300; controls) were selected and screened for variants in 27 monogenic diabetes-genes by targeted resequencing. Rare (minor allele frequency-MAF <1%) and possibly deleterious variants were collectively tested for association with early-onset T2D. The association of a genetic risk score (GRS) based on 17 GWAS-SNPs for T2D was also tested. When all rare variants were considered together, each increased the risk of early-onset T2D by 65% (allelic OR =1.64, 95% CI: 1.08-2.48, p = 0.02). Effects were similar when the 600 study participants were stratified according to their place of recruitment (Central-Southern Italy, 182 cases vs. 142 controls, or Rome urban area, 118 vs. 158, p for heterogeneity=0.53). Progressively less frequent variants showed increasingly stronger effects in the risk of early-onset T2D for those with MAF <0.001% (OR=6.34, 95% CI: 1.87-22.43, p = 0.003). One unit of T2D-GRS significantly increased the risk of early-onset T2D (OR 1.09, 95% CI: 1.01-1.18; p = 0.02). This association was stronger among rare variants carriers as compared to non-carriers (p = 0.02). Rare variants in monogenic-diabetes genes are associated with an increased risk of early-onset T2D, and interact with common T2D susceptibility variants in shaping it. These findings might help develop prediction tools to identify individuals at high risk of developing T2D in early adulthood.

Identifiants

pubmed: 35487478
pii: S1262-3636(22)00035-0
doi: 10.1016/j.diabet.2022.101353
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101353

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest No potential conflicts of interest relevant to this article were reported.

Auteurs

Serena Pezzilli (S)

Research Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.

Manoush Tohidirad (M)

Research Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.

Tommaso Biagini (T)

Unit of Bioinformatics, Fondazione IRCSS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.

Maria Giovanna Scarale (MG)

Research Unit of Diabetes and Endocrine Diseases, Fondazione IRCSS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.

Federica Alberico (F)

Research Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.

Luana Mercuri (L)

Research Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.

Gaia Chiara Mannino (GC)

Department of Medical and Surgical Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.

Monia Garofolo (M)

Section of Diabetes and Metabolic Disease, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Tiziana Filardi (T)

Department of Experimental Medicine, Sapienza University, Rome, Italy.

Yaling Tang (Y)

Research Division, Joslin Diabetes Center, Boston, MA, United States; Department of Medicine, Harvard Medical School, Boston, MA United States.

Fernando Giuffrida (F)

Research Division, Joslin Diabetes Center, Boston, MA, United States.

Christine Mendonca (C)

Research Division, Joslin Diabetes Center, Boston, MA, United States.

Francesco Andreozzi (F)

Department of Medical and Surgical Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy; Research Center for the Prevention and Treatment of Metabolic Diseases (CR METDIS), University Magna Grecia, Catanzaro, Italy.

Marco Giorgio Baroni (MG)

Department of Clinical Medicine, Life, Health & Environmental Sciences, University of L'Aquila, L'Aquila, Italy; Neuroendocrinology and Metabolic Diseases, IRCCS Neuromed, Pozzilli, Italy.

Raffaella Buzzetti (R)

Department of Experimental Medicine, Sapienza University, Rome, Italy.

Maria Gisella Cavallo (MG)

Department of Experimental Medicine, Sapienza University, Rome, Italy.

Efisio Cossu (E)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Paola D'Angelo (P)

Unit of Diabetology, Sandro Pertini Hospital, Rome, Italy.

Salvatore De Cosmo (S)

Department of Medicine, Fondazione IRCSS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.

Olga Lamacchia (O)

Unit of Endocrinology, Department of Medical and Surgical Sciences, University Hospital of Foggia, Foggia, Italy.

Frida Leonetti (F)

Diabetes Unit, Department of Medical-Surgical Sciences and Biotechnologies, Santa Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy.

Susanna Morano (S)

Department of Experimental Medicine, Sapienza University, Rome, Italy.

Lelio Morviducci (L)

Unit of Diabetology, S. Spirito Hospital - AslRM1, Rome, Italy.

Giuseppe Penno (G)

Department of Medical and Surgical Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.

Paolo Pozzilli (P)

Department of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, Rome, Italy.

Giuseppe Pugliese (G)

Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.

Giorgio Sesti (G)

Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.

Tommaso Mazza (T)

Unit of Bioinformatics, Fondazione IRCSS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.

Alessandro Doria (A)

Research Division, Joslin Diabetes Center, Boston, MA, United States; Department of Medicine, Harvard Medical School, Boston, MA United States.

Vincenzo Trischitta (V)

Research Unit of Diabetes and Endocrine Diseases, Fondazione IRCSS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; Department of Experimental Medicine, Sapienza University, Rome, Italy.

Sabrina Prudente (S)

Research Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. Electronic address: s.prudente@css-mendel.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH